Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate1 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer. The launch of the 6-month formulation of Decapeptyl® in France by Ipsen should take place during the first semester of 2010.
the details can be read here.
No comments:
Post a Comment